Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Rapt Therapeutics (RAPT) had Income from Continuous Operations of $-17.64M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-17.64M |
|
-- |
|
-- |
|
$19.54M |
|
$-19.54M |
|
$1.89M |
|
$-17.64M |
|
$-17.64M |
|
$-17.64M |
|
|
Income from Continuous Operations |
$-17.64M |
$-17.64M |
|
$-17.64M |
|
$-19.54M |
|
$-20.15M |
|
26.95M |
|
26.95M |
|
$-0.65 |
|
$-0.65 |
|
| Balance Sheet Financials | |
$172.86M |
|
$0.97M |
|
$5.55M |
|
$178.41M |
|
$13.04M |
|
-- |
|
$0.96M |
|
$14.00M |
|
$164.41M |
|
$164.41M |
|
$164.41M |
|
16.54M |
|
| Cash Flow Statement Financials | |
$-63.69M |
|
$-64.33M |
|
$0.16M |
|
$169.74M |
|
$41.89M |
|
$-127.85M |
|
$9.19M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.25 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-63.77M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-10.73% |
|
-10.73% |
|
-9.89% |
|
-10.73% |
|
$9.94 |
|
$-2.37 |
|
$-2.36 |
|